The most common side effects in clinical trial participants being treated with Entresto were hypotension, hyperkalemia, and renal impairment. Angioedema was also reported with Entresto; black patients and patients with a prior history of angioedema have a higher risk. Health care professionals should advise patients not to use Entresto with any drug from the ACE inhibitor class because the risk of angioedema is increased. When switching between Entresto and an ACE inhibitor, use of the two drugs should be separated by 36 hours.
Entresto will be available in three tablet strengths: 24/26mg, 49/51mg, and 97/103mg.
For more information call (800) 693-9993 or visit Novartis.com.